CORFLOW THERAPEUTICS AG
CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complication rates in these patients.
CORFLOW THERAPEUTICS AG
Industry:
Medical Medical Device
Founded:
2016-01-01
Address:
Baar, Zug, Switzerland
Country:
Switzerland
Website Url:
http://www.corflow-therapeutics.ch
Total Employee:
11+
Status:
Active
Contact:
+41 41 544 55 55
Email Addresses:
[email protected]
Total Funding:
16.7 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS ASP.NET IIS IIS 10
Similar Organizations
Sensome
Sensome offers micro-sensor technology to turn medical devices into connected healthcare devices.
Current Employees Featured
Founder
Investors List
415 CAPITAL
415 CAPITAL investment in Series A - CorFlow Therapeutics AG
InnoSuisse
InnoSuisse investment in Grant - CorFlow Therapeutics AG
Arshad Quadri
Arshad Quadri investment in Seed Round - CorFlow Therapeutics AG
Jean-Claude Laborde
Jean-Claude Laborde investment in Seed Round - CorFlow Therapeutics AG
Jacques R. Seguin
Jacques R. Seguin investment in Seed Round - CorFlow Therapeutics AG
Official Site Inspections
http://www.corflow-therapeutics.ch
Unable to get host informations!!!
More informations about "CorFlow Therapeutics AG"
Home - Corflow
CorFlow Therapeutics AG Neuhofstrasse 3d 6340 Baar, Switzerland; [email protected]; The CoFI-System is not approved in the United States of America. It is an investigational device limited by federal law to investigational …See details»
CorFlow Therapeutics AG - Crunchbase Company …
Organization. CorFlow Therapeutics AG . Connect to CRM . Save . Summary. Financials. People. Technology. ... Contact Email [email protected]; Phone Number +41 41 544 55 55; CorFlow Therapeutics is a …See details»
Who we are - Corflow
Cardiologist & VP Medical Affairs Medtronic Co-Founder of CorFlow Therapeutics AG, Chief Medical Officer and VP of Medical Affairs, Medtronic Coronary, RDN & Structural Heart, Santa …See details»
Our Technology - Corflow
CorFlow is developing a medical device that will be the first to diagnose MVO in real-time during PCI and serve as a treatment platform in the cath lab. ... Clinical Studies; Publication & Scientific Presentations; News. Press releases; Our …See details»
CorFlow | LinkedIn
CorFlow | 1.461 Follower:innen auf LinkedIn. CorFlow is developing a system that will be the first to detect & treat microvascular obstruction (MVO) in real time. | CorFlow was founded on …See details»
CorFlow Therapeutics AG Completes €44 Million Series B …
Sep 10, 2024 BAAR, Switzerland, September 10, 2024--CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview …See details»
CorFlow Therapeutics raises €44 million in Series B round
Sep 12, 2024 Medtech startup CorFlow Therapeutics AG has completed a €44 million in Series B funding round backed by a top-tier global syndicate of medical technology investors. The …See details»
CorFlow Therapeutics AG - startup.ch
CorFlow Therapeutics AG: Several arterial technologies have been attempted to improve microcirculation and reduce infarct size after a stent procedure. ... Corflow reports positive interim results of phase 1 clinical trials …See details»
CorFlow Therapeutics AG Completes €44 Million Series B …
Sep 10, 2024 CorFlow Therapeutics AG [email protected]. #distro. Article content. Share this article in your social network. Share this Story : CorFlow Therapeutics AG Completes €44 …See details»
CorFlow Therapeutics AG - Swiss Biotech
CorFlow Therapeutics AG ... https://corflow-therapeutics.ch/ Location. Neuhofstrasse 3D, 6340 Baar, Switzerland. Get Directions Canton. Zug; You may also be interested in . ObelysQ SA . …See details»
CorFlow Therapeutics Secures €44 Million Series B Funding to …
May 8, 2024 Baar, Switzerland-base CorFlow Therapeutics AG has raised €44 million in a Series B funding round to further develop its CoFI system, a novel diagnostic and drug …See details»
CorFlow’s CoFI System Evaluated in MOCA I First-in-Human Study …
May 19, 2023—CorFlow Therapeutics AG, a Switzerland-based developer of the CoFI controlled flow infusion system for diagnostic assessment and therapy delivery for coronary …See details»
News - Corflow
Mar 1, 2024 Press Releases BREAKING NEWS: Tuesday 10th September 2024 CorFlow Therapeutics AG Secures €44 Million Series B Financing to Advance Novel Diagnostic and …See details»
CorFlow Completes USD 9.7M in Seed Fundin - Cardiac Vascular …
Sep 12, 2018 BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG (www.corflow-therapeutics.ch) today announced that the company has completed the 2nd close of its Seed+ …See details»
CorFlow Therapeutics - Craft
CorFlow Therapeutics is a company that develops technologies for diagnosis and treatment of microvascular obstructions (MVO) in heart attack patients. It aims to provide a solution helping …See details»
CorFlow Therapeutics AG Completes €44 Million Series B …
Sep 10, 2024 CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong …See details»
Corflow reports positive interim results of phase 1 clinical trials
May 22, 2023 12.09.2024 14:00 CorFlow Therapeutics raises €44 million in Series B round. 22.05.2023 11:00 Corflow reports positive interim results of phase 1 clinical trials. 24.10.2019 …See details»
CorFlow Reports Late-Breaking Data from the "MOCA I" Clinical Trial
Jun 29, 2020 CorFlow Therapeutics (www.corflow-therapeutics.ch) is incorporated in Baar, Switzerland, and is developing proprietary technologies to measure the coronary …See details»
CorFlow Therapeutics raises $48.5M for drug delivery platform
Sep 10, 2024 CorFlow Therapeutics announced today that it raised €44 million ($48.5 million) to support its novel diagnostic and drug delivery platform. Broadview Ventures and Panakes …See details»